Marble Harbor Investment Counsel LLC Purchases 26,200 Shares of Pfizer Inc. $PFE

Marble Harbor Investment Counsel LLC increased its position in Pfizer Inc. (NYSE:PFE) by 7.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 393,121 shares of the biopharmaceutical company’s stock after acquiring an additional 26,200 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in Pfizer were worth $10,017,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Curio Wealth LLC lifted its holdings in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at about $29,000. Howard Hughes Medical Institute bought a new position in Pfizer during the second quarter valued at $30,000. Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in Pfizer in the second quarter worth $33,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.8%

NYSE:PFE opened at $27.37 on Wednesday. The firm has a 50-day simple moving average of $25.88 and a 200-day simple moving average of $25.26. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The firm has a market cap of $155.62 billion, a P/E ratio of 20.13 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. Pfizer’s revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $0.63 earnings per share. Equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. UBS Group assumed coverage on shares of Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective for the company. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a report on Thursday, February 12th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Wednesday, February 4th. Finally, TD Cowen reiterated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.